Product Information
APRODINE TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.0741 per EA under NDC 00904730260. Its NADAC has been published 176 times since May 24, 2023.
Strength
60; 2.5 mg/1; mg/1
Manufacturer
Major PharmaceuticalsNDC
00904730260
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDEApproval Type
OTC MONOGRAPH DRUG
FDA Application
M012On Market Since
11/11/2022
Pharmacological Classes
Price Statistics
The NADAC for APRODINE TABLET has been published 176 times since May 24, 2023, and over the history we have for it it has risen 58.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0741 per EA |
|---|---|
| All-time high | $0.0751 (Aug 12, 2026) |
| All-time low | $0.0420 (Oct 23, 2024) |
| 52-week high | $0.0751 |
| 52-week low | $0.0454 |
| Median price | $0.0471 |
| Average price | $0.0502 |
| Largest weekly change | +17.1% (Mar 18, 2026) |
| Weeks tracked | 176 |
| Tracking since | May 24, 2023 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pseudoephedrine HCl, Triprolidine HCl market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
alpha-Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of APRODINE TABLET?
The current National Average Drug Acquisition Cost (NADAC) for APRODINE TABLET, manufactured by Major Pharmaceuticals, is $0.0741 per EA (NDC 00904730260), effective Sep 30, 2026.
How has the price of APRODINE TABLET changed over time?
Over the history we have for it, the NADAC for APRODINE TABLET has risen 58.4%. It has been tracked across 176 weekly CMS publications since May 24, 2023.
What are the highest and lowest recorded NADAC prices for APRODINE TABLET?
Since May 24, 2023, the NADAC for APRODINE TABLET has ranged from a low of $0.0420 (Oct 23, 2024) to a high of $0.0751 (Aug 12, 2026), with a median of $0.0471 per EA.
Are there cheaper alternatives to APRODINE TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as APRODINE TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures APRODINE TABLET?
APRODINE TABLET (NDC 00904730260) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.